Reducing stroke risk in sub-Saharan Africa using combination medications
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study
This study is looking at how well a special pill that combines aspirin, a cholesterol-lowering medicine, and blood pressure medicine can help stroke survivors in sub-Saharan Africa stick to their treatment, with the goal of preventing more strokes and improving their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10909223 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of fixed-dose combination pills, which include aspirin, a statin, and blood pressure medications, to improve adherence to treatment among stroke survivors in sub-Saharan Africa. The study aims to address the high incidence of stroke and poor survival outcomes in this region by implementing these low-cost medications to reduce vascular risk factors such as hypertension and dyslipidemia. By focusing on improving medication adherence, the research seeks to lower the rates of further strokes and associated disabilities. The approach involves assessing the implementation of these combination therapies in Ghana, a low-and middle-income country facing significant healthcare challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are stroke survivors living in sub-Saharan Africa, particularly those with hypertension and dyslipidemia.
Not a fit: Patients who have not experienced a stroke or do not have the identified risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of subsequent strokes and improve the quality of life for stroke survivors in sub-Saharan Africa.
How similar studies have performed: Previous research has shown success with similar combination therapies in improving medication adherence and reducing cardiovascular risks in various populations.
Where this research is happening
San Francisco, United States
- Northern California Institute/res/edu — San Francisco, United States (Active)
Researchers
- Principal investigator: Ovbiagele, Bruce — Northern California Institute/res/edu
- Study coordinator: Ovbiagele, Bruce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.